February 9, 2023 06:37 AM EST
R&D
Pharma

PhI­II im­plo­sion forces Gala­pa­gos to scrap a fil­ing plan for fil­go­tinib

Amber Tong

Gala­pa­gos is block­ing off one more de­vel­op­ment path for fil­go­tinib, its JAK in­hibitor with a check­ered his­to­ry, in the wake of a neg­a­tive Phase III …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times